News - Oncology

Filter

Current filters:

Oncology

Popular Filters

100 to 124 of 1469 results

NICE guidance will deprive UK patients with newly-diagnosed advanced melanoma of Yervoy

25-02-2014

US drug major Bristol-Myers Squibb today expressed its disappointment that the UK drugs watchdog the…

Bristol-Myers SquibbNorthern EuropeOncologyPharmaceuticalPricingRegulationUKYervoy

IQWiG now finds “major” benefit for Xtandi

24-02-2014

In an early benefit assessment under Germany’s Act on the Reform of the Market for Medicinal Products…

Astellas PharmaGermanyMedivationNorthern EuropeOncologyPharmaceuticalPricingRegulationXtandi

Onconova tanks, as lead drug rigosertib fails in Ph III MDS study

Onconova tanks, as lead drug rigosertib fails in Ph III MDS study

21-02-2014

US biotech firm Onconova Therapeutics saw its shares plunge 37% to $8.70 in pre-market trading yesterday…

Baxter InternationalOncologyOnconova TherapeuticsPharmaceuticalResearchrigosertib

Avastin seen to prolong life for women with advanced cervical cancer

Avastin seen to prolong life for women with advanced cervical cancer

20-02-2014

Swiss drug major Roche’s blockbuster cancer drug Avastin (bevacizumab) can extend the lives of women…

AvastinOncologyPharmaceuticalResearchRoche

Genentech regains its dominance in image among oncologists

Genentech regains its dominance in image among oncologists

20-02-2014

Genentech, the biotechnology subsidiary of Swiss drug major Roche, has made notable gains as the top…

AmgenBiotechnologyCelgeneGenentechHematologyMarkets & MarketingNovartisOncologyResearch

Eli Lilly’s ramucirumab Ph III lung cancer trial meets primary endpoint

Eli Lilly’s ramucirumab Ph III lung cancer trial meets primary endpoint

19-02-2014

US pharma major Eli Lilly has revealed that the REVEL trial showed that its ramucirumab improved survival…

Eli LillyOncologyPharmaceuticalramucirumabResearch

Novartis’ LDE225 met primary endpoint in pivotal trial for advanced basal cell carcinoma

Novartis’ LDE225 met primary endpoint in pivotal trial for advanced basal cell carcinoma

19-02-2014

Swiss drug major Novartis says the pivotal trial of the investigational oral compound LDE225 (sonidegib)…

LDE225NovartisOncologyPharmaceuticalResearchsonidegib

IQWiG finds that added benefit of Boehringer’s Giotrif depends on mutation status

IQWiG finds that added benefit of Boehringer’s Giotrif depends on mutation status

19-02-2014

The German Institute for Quality and Efficiency in Health Care (IQWiG), in an early benefit assessment…

Boehringer IngelheimGermanyGiotrifNorthern EuropeOncologyPharmaceuticalPricingRegulation

Mologen raises cash to fund Phase III trial of colorectal cancer drug

19-02-2014

German drug development company Mologen has raised 15.7 million euros ($21.6 million) in order to fund…

FinancialGermanyOncologyPharmaceuticalResearch

Call for EU regulators to get tougher on pediatric clinical trials for cancer drugs

Call for EU regulators to get tougher on pediatric clinical trials for cancer drugs

18-02-2014

Children with cancer are being denied potentially life-saving drugs because European Union rules are…

EuropeOncologyPharmaceuticalRegulation

Servier and Cellectis collaborate on leukemia and solid tumors candidates

Servier and Cellectis collaborate on leukemia and solid tumors candidates

18-02-2014

Allogeneic CAR T-cell therapies specialist Cellectis has signed a strategic collaboration agreement with…

CellectisLicensingOncologyPharmaceuticalResearchServierUCART19

Scancell granted orphan drug designation for melanoma drug

Scancell granted orphan drug designation for melanoma drug

17-02-2014

UK-based immunotherapy company Scancell has been granted orphan drug designation for its SCIB1 ImmunoBody…

ImmunologicalsOncologyPharmaceuticalRegulationScancellSCIB1UKUSA

X-Chem licenses drug discovery program to Bayer

X-Chem licenses drug discovery program to Bayer

17-02-2014

X-Chem Inc, a privately held US biotechnology company focused on applying its innovative drug discovery…

BayerBiotechnologyLicensingOncologyX-Chem

Novartis to acquire CoStim, expanding cancer immunotherapy research program

Novartis to acquire CoStim, expanding cancer immunotherapy research program

17-02-2014

Swiss drug major Novartis said this morning that it is broadening its cancer immunotherapy research program…

BiotechnologyCoStim PharmaceuticalsMergers & AcquisitionsNovartisOncology

AVEO and Astellas finally terminate tivozanib collaboration

14-02-2014

US biotech firm AVEO Oncology and Japanese drug major Astellas Pharma are to end their worldwide collaboration…

Astellas PharmaAVEO OncologyBiotechnologyLicensingOncologytivozanib

Teva gains full FDA approval of CML drug Synribo

Teva gains full FDA approval of CML drug Synribo

14-02-2014

Israel-based Teva Pharmaceutical Industries says the US Food and Drug Administration has granted full…

North AmericaOncologyPharmaceuticalRegulationSynriboTeva Pharmaceutical IndustriesUSA

Aurigene and Pierre Fabre announce licensing agreement for novel immunotherapy

Aurigene and Pierre Fabre announce licensing agreement for novel immunotherapy

13-02-2014

Privately-owned Pierre Fabre and Aurigene, a leading Indian biotech company, have entered into an agreement…

Aurigene DiscoveryBiotechnologyFranceIndiaLicensingOncologyPierre Fabre

Exelixis appoints Jeffrey Hessekiel as Executive Vice President and General Counsel

Exelixis appoints Jeffrey Hessekiel as Executive Vice President and General Counsel

13-02-2014

Exelixis (NASDAQ: EXEL) have announced the appointment of Jeffrey Hessekiel as executive vice president…

BiotechnologyBoardroomExelixisOncologyUSA

FDA expands approval of Imbruvica to treat chronic lymphocytic leukemia

FDA expands approval of Imbruvica to treat chronic lymphocytic leukemia

13-02-2014

The US Food and Drug Administration yesterday expanded the approved use of US health care giant Johnson…

ImbruvicaJanssen BiotechJohnson & JohnsonNorth AmericaOncologyPharmaceuticalPharmacyclicsRegulationUSA

Roche’s breast cancer drug Kadcyla debuts in UK

Roche’s breast cancer drug Kadcyla debuts in UK

13-02-2014

Swiss drug major Roche’s Kadcyla (ado-trastuzumab emtansine or T-DM1) is now available for UK patients…

KadcylaMarkets & MarketingNorthern EuropeOncologyPharmaceuticalRocheUK

Health Canada approves Celgene’s Pomalyst for multiple myeloma

Health Canada approves Celgene’s Pomalyst for multiple myeloma

12-02-2014

Regulatory agency Health Canada has approved US biotech firm Celgene’s drug Pomalyst (pomalidomide…

BiotechnologyCanadaCelgeneNorth AmericaOncologyPomalystRegulation

Regeneron revenues leap, boosted by stronger than expected sales of Eylea

Regeneron revenues leap, boosted by stronger than expected sales of Eylea

11-02-2014

US biotech firm Regeneron Pharmaceuticals reports that its blockbuster ophthalmic drug Eylea (aflibercept)…

BayerBiotechnologyEyleaFinancialOncologyOphthalmicsRegeneronResearchSanofiZaltrap

100 to 124 of 1469 results

Company Spotlight

Fibrotech

Fibrotech

Back to top